Skip to main content
. Author manuscript; available in PMC: 2009 Jan 6.
Published in final edited form as: Vaccine. 2008 Jul 1;26(34):4314–4319. doi: 10.1016/j.vaccine.2008.06.049

Figure 2. In vivo treatment experiment in tumor-bearing mice treated with MD5-1 mAb and/or CRT/E7(detox) DNA vaccine.

Figure 2

(A) Schematic diagram showing the treatment regimen of MD5-1 mAb and/or the CRT/E7(detox) DNA vaccine. (B) Line graph depicting the tumor volume in TC-1 tumor-bearing mice treated with MD5-1 mAb and/or CRT/E7(detox) DNA vaccine. Groups of C57BL/6 mice (5 per group) were subcutaneously challenged with 5 × 104/mouse of TC-1 tumor cells on day 0. Tumor-bearing mice were treated with 0.25 mg/mouse of MD5-1 mAb intraperitoneally on day 8. Three days later, the mice were vaccinated with or without DNA encoding CRT/E7(detox) DNA via gene gun in the amount of 2 ug/mouse three times with 4-day intervals. A group of mice treated with the DNA vaccine alone were used as a control. Data are represented as mean±s.e. Data shown are representative of two experiments performed.